文献速递眼底病与葡萄膜炎青光眼

模拟复杂的年龄相关眼病

Modeling complex age-related eye disease.
PubMed 文献 · Prog Retin Eye Res · 2024-02-15

本文综述了模拟年龄相关黄斑变性(AMD)和青光眼等复杂眼病的主要策略,重点讨论了常用小鼠模型的优势与局限,并比较了非人灵长类、兔、患者来源视网膜类器官及人供体眼等替代模型。作者指出小动物模型能否真实再现疾病进展和视力丧失仍不确定,而生物学年龄而非时序年龄可能更决定易感性。

要点

  • AMD和青光眼遗传力较高(>50%),但携带风险变异者多数并不发病。
  • 小鼠模型受寿命短、无黄斑和真筛板、基因序列差异等限制。
  • 小动物模型不适于研究视力丧失自然进程及新疗法的疗效与安全性。

核心结论

  • 小鼠模型已并将继续改善对年龄相关眼病病理生物学的理解,但其能否真实再现患者疾病进展和视力丧失仍不确定。
  • 由于解剖生理及药代动力学差异,小动物模型不适于研究视力丧失自然进展或新疗法疗效与安全性。
  • 生物学年龄而非时序年龄可能决定青光眼和AMD易感性,快速衰老的小型啮齿类可使研究更及时且经济可行。

研究设计与样本

  • 综述,主要讨论最常用的小鼠模型,并涉及非人灵长类、兔、患者来源视网膜类器官和人供体眼等替代模型。

主要发现

  • AMD和青光眼遗传力均>50%,但大量携带AMD或青光眼相关遗传风险变异的个体终身不发病。
  • 多种环境与生活方式因素参与并调节AMD和青光眼的发病与进展。
  • 小鼠存在寿命较短、体型与异速生长、缺乏黄斑和真筛板、某些基因缺失及序列差异和染色体位置不同等顾虑。
  • 小动物模型因上述解剖生理及药代动力学和药效学差异,不适于研究视力丧失自然进展或新疗法疗效与安全性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 小动物模型能否真实再现患者疾病进展和视力丧失仍不确定,令人怀疑其用于测试新型基因或药物治疗的价值。
  • 小鼠寿命较短、体型与异速生长、缺乏黄斑和真筛板、某些基因缺失及序列差异和染色体位置不同。
  • 小动物模型因解剖生理及药代动力学和药效学差异,不适于研究视力丧失自然进展或新疗法疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Modeling complex eye diseases like age-related macular degeneration (AMD) and glaucoma poses significant challenges, since these conditions depend highly on age-related changes that occur over several decades, with many contributing factors remaining unknown. Although both diseases exhibit a relatively high heritability of >50%, a large proportion of individuals carrying AMD- or glaucoma-associated genetic risk variants will never develop these diseases. Furthermore, several environmental and lifestyle factors contribute to and modulate the pathogenesis and progression of AMD and glaucoma. Several strategies replicate the impact of genetic risk variants, pathobiological pathways and environmental and lifestyle factors in AMD and glaucoma in mice and other species. In this review we will primarily discuss the most commonly available mouse models, which have and will likely continue to improve our understanding of the pathobiology of age-related eye diseases. Uncertainties persist whether small animal models can truly recapitulate disease progression and vision loss in patients, raising doubts regarding their usefulness when testing novel gene or drug therapies. We will elaborate on concerns that relate to shorter lifespan, body size and allometries, lack of macula and a true lamina cribrosa, as well as absence and sequence disparities of certain genes and differences in their chromosomal location in mice. Since biological, rather than chronological, age likely predisposes an organism for both glaucoma and AMD, more rapidly aging organisms like small rodents may open up possibilities that will make research of these diseases more timely and financially feasible. On the other hand, due to the above-mentioned anatomical and physiological features, as well as pharmacokinetic and -dynamic differences small animal models are not ideal to study the natural progression of vision loss or the efficacy and safety of novel therapies. In this context, we will also discuss the advantages and pitfalls of alternative models that include larger species, such as non-human primates and rabbits, patient-derived retinal organoids, and human organ donor eyes.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Becker S, L'Ecuyer Z, Jones BW, et al. Modeling complex age-related eye disease. Prog Retin Eye Res. 2024. PMID: 38365085. doi:10.1016/j.preteyeres.2024.101247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。